. 2006 Aug 26;48(10):703–713. doi: 10.1007/s00234-006-0122-z

Table 2.

rCBV and survival in the series and in those with primary tumours. PFS and OS were calculated from start date of PCV (n number of cases, nc not calculated, nr median survival not reached). Contrast enhancement (present vs absent), age (<50 vs ≥50 years), ECOG performance status (0–1 vs ≥2) and gender (male vs female) were not significantly related to PFS or OS

			n	Progression-free survival (months)			Overall survival (months)
			n	Median (95%CI)	P value^a	P value^b	Median (95%CI)	P value^a	P value^b
All tumours	Loss of 1p36 and 19q13	Yes	16	>56 (nr)	0.005		>56 (nr)	0.020
	Loss of 1p36 and 19q13	No	17	8 (0–21)			>49 (nr)
	Histopathology subtype	Oligodendroglioma	11	>56 (nr)	0.055	0.187	>56 (nr)	0.113	0.288
	Histopathology subtype	Oligoastrocytoma	21	8 (9–41)			50 (9–91)
	Histopathology grade	II	19	>56 (nr)	0.004	0.002	>56 (nr)	0.007	0.012
	Histopathology grade	III	14	4 (8–26)			21 (8–34)
	rCBV	Low	14	>46 (nr)	0.766	0.003	>49 (nr)	0.585	0.002
	rCBV	High	19	46 (nc)			>56 (nr)
Primary tumours	Loss of 1p36 and 19q13	Yes	14	>56 (nr)	0.037		>56 (nr)	0.056
	Loss of 1p36 and 19q13	No	12	>39 (nr)			49
	Histopathology subtype	Oligodendroglioma	10	>56 (nr)	0.055	0.137	All censored	0.092	0.209
	Histopathology subtype	Oligoastrocytoma	16	46 (6–86)			50 (6–101)
	Histopathology grade	II	17	>56 (nr)	0.047	0.009	>56 (nr)	0.048	0.041
	Histopathology grade	III	9	6 (13–37)			50 (nc)
	rCBV	Low	12	>46 (nr)	0.681	0.007	>49 (nr)	0.611	0.003
	rCBV	High	14	>56 (nr)			>56 (nr)

^aProbability calculated by the Log-Rank test.

^bProbability calculated by the Log-Rank test after adjustment for 1p/19q genotype.